Survival improves when cancer is detected early. However,~ 50% of cancers are at an
advanced stage when diagnosed. Early detection of cancer or precancerous change allows …

Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Summary In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …

Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers,
treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the …

Human cancer cell lines are the workhorse of cancer research. Although cell lines are
known to evolve in culture, the extent of the resultant genetic and transcriptional …

Immunotherapy is a promising treatment for triple-negative breast cancer (TNBC), but
patients relapse, highlighting the need to understand the mechanisms of resistance. We …